Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory biomarkers and cardiovascular dysfunction in systemic inflammatory conditions (Part II)
2007-005464-26Phase 4Completed
- Sponsor
- King's College London
- Start
- Apr 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of certolizumab pegol, infliximab, etanercept and adalimumab in rheumatoid arthritis (RA) and systemic inflammatory disease (not a recognized specific disease entity), sponsored by King's College London. Primary endpoints: Change in cardiovascular function parameters and Change in flow-mediated dilatation (FMD). Started Apr 2008; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)systemic inflammatory disease (not a recognized specific disease entity)
Beyond the preview
Go deeper on 2007-005464-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005464-26.